Nephros (NEPH) Competitors $1.46 +0.01 (+0.69%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NEPH vs. SSKN, CTSO, LUCD, COCH, ICAD, ALUR, CLGN, APYX, CODX, and SURGShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include STRATA Skin Sciences (SSKN), Cytosorbents (CTSO), Lucid Diagnostics (LUCD), Envoy Medical (COCH), iCAD (ICAD), Allurion Technologies (ALUR), CollPlant Biotechnologies (CLGN), Apyx Medical (APYX), Co-Diagnostics (CODX), and SurgePays (SURG). These companies are all part of the "medical equipment" industry. Nephros vs. STRATA Skin Sciences Cytosorbents Lucid Diagnostics Envoy Medical iCAD Allurion Technologies CollPlant Biotechnologies Apyx Medical Co-Diagnostics SurgePays Nephros (NASDAQ:NEPH) and STRATA Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking. Which has preferable earnings & valuation, NEPH or SSKN? Nephros has higher earnings, but lower revenue than STRATA Skin Sciences. Nephros is trading at a lower price-to-earnings ratio than STRATA Skin Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.24M1.08-$1.58M-$0.13-11.22STRATA Skin Sciences$33.36M0.37-$10.83M-$2.43-1.21 Which has more risk & volatility, NEPH or SSKN? Nephros has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, STRATA Skin Sciences has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Is NEPH or SSKN more profitable? Nephros has a net margin of -9.40% compared to STRATA Skin Sciences' net margin of -25.40%. Nephros' return on equity of -15.64% beat STRATA Skin Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Nephros-9.40% -15.64% -11.43% STRATA Skin Sciences -25.40%-50.45%-14.29% Do analysts rate NEPH or SSKN? Nephros currently has a consensus target price of $5.00, suggesting a potential upside of 242.72%. Given Nephros' higher probable upside, analysts clearly believe Nephros is more favorable than STRATA Skin Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00STRATA Skin Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community favor NEPH or SSKN? STRATA Skin Sciences received 211 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 63.90% of users gave STRATA Skin Sciences an outperform vote while only 41.38% of users gave Nephros an outperform vote. CompanyUnderperformOutperformNephrosOutperform Votes1241.38% Underperform Votes1758.62% STRATA Skin SciencesOutperform Votes22363.90% Underperform Votes12636.10% Does the media favor NEPH or SSKN? In the previous week, Nephros and Nephros both had 1 articles in the media. Nephros' average media sentiment score of 0.33 beat STRATA Skin Sciences' score of -0.50 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral STRATA Skin Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do insiders and institutionals hold more shares of NEPH or SSKN? 41.1% of Nephros shares are owned by institutional investors. Comparatively, 32.4% of STRATA Skin Sciences shares are owned by institutional investors. 4.1% of Nephros shares are owned by company insiders. Comparatively, 39.0% of STRATA Skin Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryNephros beats STRATA Skin Sciences on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.38M$4.41B$5.50B$8.53BDividend YieldN/A42.37%5.13%4.14%P/E Ratio-11.2239.21116.1015.23Price / Sales1.0864.601,496.2597.74Price / CashN/A49.0939.7434.10Price / Book1.824.264.775.07Net Income-$1.58M$11.52M$119.06M$225.46M7 Day Performance5.72%1.06%0.80%0.37%1 Month Performance-7.08%0.92%5.65%3.57%1 Year Performance-9.94%39.37%36.75%29.43% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros2.6342 of 5 stars$1.46+0.7%$5.00+242.7%-15.2%$15.38M$14.24M-11.2230Upcoming EarningsSSKNSTRATA Skin Sciences0.5542 of 5 stars$3.08-1.6%N/A-39.4%$12.85M$32.73M-1.27120News CoverageCTSOCytosorbents1.9252 of 5 stars$1.01flat$2.00+98.0%-32.0%$54.85M$32.93M-1.91186Upcoming EarningsAnalyst ForecastNews CoverageLUCDLucid Diagnostics2.2298 of 5 stars$0.97-3.0%$3.94+306.3%-29.2%$52.32M$3.80M-0.7970Gap DownCOCHEnvoy Medical3.5817 of 5 stars$2.65+7.3%$7.92+198.7%+104.0%$51.94M$302,000.000.0034News CoverageGap UpICADiCAD0.464 of 5 stars$1.86+0.5%N/A+37.9%$49.36M$18.80M-16.9167Short Interest ↑ALURAllurion Technologies1.9231 of 5 stars$0.71-2.7%$2.88+303.3%-83.9%$45.88M$47.59M-0.81501Gap UpCLGNCollPlant Biotechnologies2.1757 of 5 stars$3.74-0.5%$11.00+194.1%-43.5%$42.83M$689,000.00-2.4370High Trading VolumeAPYXApyx Medical4.5297 of 5 stars$1.17-4.9%$5.00+327.4%-49.1%$40.53M$49.03M-1.43270Upcoming EarningsCODXCo-Diagnostics3.2389 of 5 stars$1.21-0.8%$1.50+24.0%+13.1%$38.61M$9.14M-0.96100Upcoming EarningsShort Interest ↑SURGSurgePays3.6333 of 5 stars$1.67+9.2%$9.00+438.9%-64.2%$32.97M$112.99M18.5622News Coverage Related Companies and Tools Related Companies STRATA Skin Sciences Competitors Cytosorbents Competitors Lucid Diagnostics Competitors Envoy Medical Competitors iCAD Competitors Allurion Technologies Competitors CollPlant Biotechnologies Competitors Apyx Medical Competitors Co-Diagnostics Competitors SurgePays Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NEPH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
